A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Endeavor Biomedicines, Inc.

Criteria

Inclusion Criteria:

• Females or males greater than or equal to 18 years of age. Females and males between 12 and 17 years of age (inclusive) may be enrolled if deemed appropriate after review of an X-ray with the sponsor for evaluation of growth plate development

• Has histologically or cytologically confirmed solid tumor that harbors a PTCH1 loss of function mutation, identified via genomic sequencing routinely performed at a CLIA certified laboratory

• Able to take medication orally

• Patients must be refractory to all standard of care therapy, or standard or curative therapy does not exist, or the patient has documented their refusal of standard of care therapies

• Patients willing to sign and have a full understanding of the informed consent form

• Life expectancy of ≥ 3 months

Exclusion Criteria:

• Concurrent administration of any anti-cancer therapies (e.g., chemotherapy, other targeted therapy) other than those administered in this study

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Patients with indwelling catheters are allowed

• Malignancies other than the primary tumor type within 5 years prior to study start, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS > 90%) treated with expected curative outcome (prior history of in situ basal or squamous cell skin cancer if completely excised, localized prostate cancer that is managed by surveillance, ductal carcinoma in situ treated surgically with curative intent are allowed)

• History of clinically significant autoimmune disease requiring prescription systemic therapy in the last two years prior to study start; patients with controlled hypothyroidism may be considered after evaluation by the Investigator.

• Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)

• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study start, unstable arrhythmias, or unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician

• Refractory nausea and vomiting, malabsorption, external biliary shunt or significant bowel resection that would preclude adequate absorption of investigational product

• Major surgical procedure within 28 days prior to study start or anticipation of need for a major surgical procedure during the course of the study

• Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to study start

• Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start

• Unresolved toxicity of ≥ CTCAE Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, platinum-induced neurotoxicity and endocrine disease or ailments that are stable)

• Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 30 days after their final study dose

• Females that are pregnant or nursing

• Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose

• Males who are unwilling to refrain from sperm donation for the duration of the study and for 30 days after their final study dose

• Patients with a history of a severe allergic reaction, anaphylactic reaction or known hypersensitivity to any component of ENV-101

• Patients who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with a study investigative site or the study Sponsor